title: Effects of sepsis on mast cells in rat dura mater: influence of L-NAME and VIP.
abstract: 1. The influence of lipopolysaccharide (LPS)-induced sepsis on the various mast cell phenotypes of rat dura mater were examined both by immunohistochemical and biochemical methods. 2. Three different populations of mast cells were identified in control rats: connective tissue type mast cells (CTMC) which contain rat mast cell protease1 (RMCP1), histamine, serotonin and heparin, mucosal type mast cells (MMC) which contain RMCP2, histamine and serotonin, and intermediate type which contains both RMCP1 and RMCP2 and probably various proportions of amines and heparin. 3. LPS (25 mg kg(-1) i.p.) caused changes in the proportions of the various types of mast cells. The number of MMC and intermediate type mast cells significantly increased and the number of mast cells immunopositive for both heparin and serotonin significantly decreased. Biochemical analysis showed that the histamine concentration of dura increased while its serotonin concentration decreased. 4. While vasoactive intestinal peptide (VIP) (25 ng kg(-1) i.p.) appears to potentiate LPS effects on dura mater mast cells, non-selective inhibition of nitric oxide (NO) synthase by N(g)-nitro-L-arginine methyl ester (L-NAME) (30 mg kg(-1) i.p.) did not influence sepsis-induced mast cell changes. 5. These findings suggest that mast cells of dura mater may play a role in brain protection during sepsis.
authors.affiliation: Vascular Pharmacology and Physiopathology, CNRS, UMR 5017, University Bordeaux II, 146, rue Leo Saignat, 33076 Bordeaux, France.
authors.forename: F
authors.initials: F
authors.lastname: Tore
authors.forename: A M
authors.initials: AM
authors.lastname: Reynier-Rebuffel
authors.forename: N
authors.initials: N
authors.lastname: Tuncel
authors.forename: J
authors.initials: J
authors.lastname: Callebert
authors.forename: P
authors.initials: P
authors.lastname: Aubineau
mesh_terms: D000818:Animals; D002452:Cell Count; D053818:Chymases; D004388:Dura Mater / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006493:Heparin / Q000378:metabolism; D006632:Histamine / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008297:Male; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D018613:Microscopy, Confocal; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000139:chemically induced / Q000503:physiopathology*; D012697:Serine Endopeptidases / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D012701:Serotonin; D014660:Vasoactive Intestinal Peptide; D006632:Histamine; D006493:Heparin; D012697:Serine Endopeptidases; D053818:Chymases; D019331:NG-Nitroarginine Methyl Ester